Effects of Treadmill Walking Speeds With Cognitive Training on HRV, Gait, and Motor-Cognitive in Elderly With Type 2 DM
NCT07920510, Not applicable, Active not recruiting, University of Phayao
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of Treadmill Walking Speeds With Cognitive Training on HRV, Gait, and Motor-Cognitive in Elderly With Type 2 DM | ClinicalTrials.gov |
| NCT number | NCT07920510 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Phayao | ClinicalTrials.gov |
| Conditions | Diabetes Mellitus, Type 2 | ClinicalTrials.gov |
| Interventions | Individualized Higher-Speed Treadmill Walking, Individualized Preferred-Speed Treadmill Walking, Cognitive training, Fall-Prevention Health Education | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Standard Deviation of Normal-to-Normal Intervals (SDNN) | Baseline and immediately after the 6-week intervention. | Resting heart rate variability is assessed using the SA-3000P heart rate variability analyzer under standardized seated resting conditions. SDNN is the standard deviation of normal-to-normal R-R intervals and is reported in milliseconds (ms). Higher SDNN values indicate greater overall heart rate variability. | ClinicalTrials.gov |
| Primary | Change in Root Mean Square of Successive Differences (RMSSD) | Baseline and immediately after the 6-week intervention. | Resting heart rate variability is assessed using the SA-3000P heart rate variability analyzer under standardized seated resting conditions. RMSSD is calculated from successive normal-to-normal R-R interval differences and is reported in milliseconds (ms). RMSSD is used as an index of short-term cardiac vagal modulation. | ClinicalTrials.gov |
| Primary | Change in Timed Up and Go Dual-Task Test Completion Time | Baseline and immediately after the 6-week intervention. | Motor-cognitive mobility is assessed using the Timed Up and Go Test performed under a concurrent secondary-task condition. Participants rise from a chair, walk 3 meters, turn, return, and sit down while carrying a cup of water. Completion time is recorded in seconds. A shorter completion time indicates better performance under dual-task conditions. | ClinicalTrials.gov |
| Primary | Change in Figure-of-8 Walk Dual-Task Test Completion Time | Baseline and immediately after the 6-week intervention. | Dual-task walking performance is assessed using the Figure-of-8 Walk Test under a concurrent secondary-task condition. Participants walk a figure-of-8 course around two markers while carrying a cup of water. Completion time is recorded in seconds. A shorter completion time indicates better performance. | ClinicalTrials.gov |
| Secondary | Retention of SDNN Following Training Cessation | 4 weeks after completion of the 6-week intervention (Week 10 from baseline). | Resting SDNN is assessed using the SA-3000P heart rate variability analyzer to determine whether changes observed following treadmill walking and cognitive training are maintained after cessation of supervised training. SDNN is reported in milliseconds (ms). | ClinicalTrials.gov |
| Secondary | Retention of RMSSD Following Training Cessation | 4 weeks after completion of the 6-week intervention (Week 10 from baseline). | Resting RMSSD is assessed using the SA-3000P heart rate variability analyzer to determine retention of cardiac autonomic adaptations after cessation of supervised training. RMSSD is reported in milliseconds (ms). | ClinicalTrials.gov |
| Secondary | Change in 10-Meter Walk Test at Preferred Walking Pace | Baseline, immediately after the 6-week intervention, and 4 weeks after completion of the intervention (Week 10 from baseline). | Walking performance is assessed using the 10-Meter Walk Test at the participant's preferred walking pace. Participants walk along a standardized level walkway, and walking performance is recorded as completion time in seconds. A shorter completion time indicates faster walking performance. | ClinicalTrials.gov |
| Secondary | Change in 10-Meter Walk Test at Fast Walking Pace | Baseline, immediately after the 6-week intervention, and 4 weeks after completion of the intervention (Week 10 from baseline). | Fast walking performance is assessed using the 10-Meter Walk Test. Participants are instructed to walk as fast as safely possible. Completion time is recorded in seconds. A shorter completion time indicates better fast-walking performance. | ClinicalTrials.gov |
| Secondary | Change in Five Times Sit-to-Stand Test | Baseline, immediately after the 6-week intervention, and 4 weeks after completion of the intervention (Week 10 from baseline). | Functional lower-extremity performance is assessed using the Five Times Sit-to-Stand Test. Participants rise from and return to a seated position five consecutive times as quickly and safely as possible. Completion time is recorded in seconds. A shorter time indicates better functional performance. | ClinicalTrials.gov |
| Secondary | Change in Timed Up and Go Test | Baseline, immediately after the 6-week intervention, and 4 weeks after completion of the intervention (Week 10 from baseline). | Functional mobility and dynamic balance are assessed using the Timed Up and Go Test. Participants stand from a chair, walk 3 meters, turn, return, and sit down. Completion time is recorded in seconds. A shorter completion time indicates better mobility. | ClinicalTrials.gov |
| Secondary | Change in Figure-of-8 Walk Test | Baseline, immediately after the 6-week intervention, and 4 weeks after completion of the intervention (Week 10 from baseline). | Curved-path walking and dynamic balance are assessed using the Figure-of-8 Walk Test. Participants complete one figure-of-8 walking course around two markers positioned 1.5 meters apart. Completion time is recorded in seconds, with shorter values indicating better performance. | ClinicalTrials.gov |
| Secondary | Change in Stepping Trail-Making Test | Baseline, immediately after the 6-week intervention, and 4 weeks after completion of the intervention (Week 10 from baseline). | Motor-cognitive performance is assessed using the Stepping Trail-Making Test. Participants step sequentially on numbered targets from 1 to 16 as quickly and accurately as possible. Completion time, including time required to correct errors, is recorded in seconds. A shorter completion time indicates better motor-cognitive performance. | ClinicalTrials.gov |
| Secondary | Change in High-Frequency Normalized Power (HFnu) | Baseline, immediately after the 6-week intervention, and 4 weeks after completion of the intervention (Week 10 from baseline). | High-frequency normalized power is obtained from resting heart rate variability analysis using the SA-3000P. HFnu represents the relative contribution of high-frequency power to the analyzed frequency-domain spectrum and is reported in normalized units. | ClinicalTrials.gov |
| Secondary | Change in Low-Frequency Normalized Power (LFnu) | Baseline, immediately after the 6-week intervention, and 4 weeks after completion of the intervention (Week 10 from baseline). | Low-frequency normalized power is obtained from resting heart rate variability analysis using the SA-3000P and is reported in normalized units. | ClinicalTrials.gov |
| Secondary | Change in Low-Frequency to High-Frequency Power Ratio (LF/HF) | Baseline, immediately after the 6-week intervention, and 4 weeks after completion of the intervention (Week 10 from baseline). | The LF/HF ratio is derived from frequency-domain heart rate variability analysis using the SA-3000P. The ratio is reported as a dimensionless HRV index and will be interpreted as an exploratory frequency-domain measure rather than as a direct measure of sympathovagal balance. | ClinicalTrials.gov |
| Secondary | Change in 2-Minute Step Test Performance | Baseline, immediately after the 6-week intervention, and 4 weeks after completion of the intervention (Week 10 from baseline). | Functional aerobic endurance is assessed using the 2-Minute Step Test. Participants perform repeated stepping in place for 2 minutes, raising the knees to the standardized target height. The total number of completed steps is recorded. A higher number of steps indicates better functional endurance. | ClinicalTrials.gov |
| Secondary | Change in Stroop Test Performance | Baseline, immediately after the 6-week intervention, and 4 weeks after completion of the intervention (Week 10 from baseline). | Cognitive performance, particularly attention, inhibitory control, and executive function, is assessed using the Stroop Test. Performance is recorded according to the standardized scoring procedure used in the study. Higher scores indicate better cognitive performance. | ClinicalTrials.gov |
| Secondary | Change in Right-Hand Ruler Drop Test Performance | Baseline, immediately after the 6-week intervention, and 4 weeks after completion of the intervention (Week 10 from baseline). | Simple visuomotor reaction performance is assessed using the Ruler Drop Test with the right hand. A ruler is released without warning and the participant attempts to catch it as quickly as possible. The distance fallen before the ruler is caught is recorded in centimeters. A shorter distance indicates faster reaction performance. | ClinicalTrials.gov |
| Secondary | Change in Left-Hand Ruler Drop Test Performance | Baseline, immediately after the 6-week intervention, and 4 weeks after completion of the intervention (Week 10 from baseline). | Simple visuomotor reaction performance is assessed using the Ruler Drop Test with the left hand. A ruler is released without warning and the participant attempts to catch it as quickly as possible. The distance fallen before the ruler is caught is recorded in centimeters. A shorter distance indicates faster reaction performance. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)